FIELD: chemistry.
SUBSTANCE: invention relates to the field of organic chemistry, namely a heterocyclic compound of formula (I) or a stereo-isomer thereof or a pharmaceutically acceptable salt, where X is CH or N; Z is (i) NH(CH2)nCHR1Ar, where n is 0 or 1, or (ii) is 1-alkyl-4-aryl-pyrrolidin-3-ylamine, where alkyl is C1 alkyl, optionally substituted with a phenyl ring, and aryl is methoxy substituted phenyl; R1 is (a) hydrogen, (b) C1-C6 alkyl optionally substituted with a hydroxyl group, (c) from 4 to 5 member heterocycle containing 1 hetero atom selected from N, where the heterocycle is optionally substituted with one group selected from the group consisting of halogen, or (d) 5 member heteroaryl containing 1 or 2 hetero atoms selected from N, where heteroaryl is optionally substituted with one group selected from C1-6 alkyl; Ar is phenyl, pyridinyl or indolyl optionally substituted with from 1 to 2 groups independently selected from (a) C1-6 alkoxy, (b) halogen, (c) C1-6 halogenalkoxy, (d) cyano, (e) benzyl, (f) phenoxy, where said phenoxy is optionally substituted with halogen or C1-6 alkyl, (g) 4-methylpiperazin-1-yl or (h) heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl and pyrazolyl, where said heteroaryl is optionally substituted with one C1-10 alkyl; R2 is selected from the group consisting of (a) C1-5 hydroxyalkyl, (b) C1-6 haloalkyl, (c) heterocyclyl, where said heterocyclyl is selected from the group consisting of tetrahydropyranyl, tetrahydrofuranyl, 2-oxa-bicyclo[2,2,1]heptan-5-yl and pyrrolidinyl, and where said heterocyclyl is optionally substituted with 1 group independently selected from the group consisting of halogen, C1-3 hydroxyalkyl or oxo, (d) heteroaryl, where said heteroaryl is selected from the group consisting of pyrazolyl and pyridinyl, and where said heteroaryl is optionally substituted with 1-2 C1-3 alkyl groups, (e) C3 cycloalkyl-C1-2 alkyl, where said C3 cycloalkyl-C1-2 alkyl is optionally substituted with hydroxyl. Invention is also relates to a pharmaceutical composition based on a compound of formula (I), method of ERK protein kinase activity inhibiting, method of a hyperproliferative disorder treating or severity reducing and the use of a compound of formula (I).
.
EFFECT: produced are new heterocyclic compounds, which are useful in hyperproliferative disorder treating.
29 cl, 3 tbl, 34 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | 2011 |
|
RU2617405C2 |
| NOVEL DERIVATIVE OF PURINYLPYRIDINYLAMINO-2,4-DIFLUOROPHENYLSULPHONAMIDE, ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD OF ITS OBTAINING AND PHARMACEUTICAL COMPOSITION, WHICH HAS INHIBITION ACTIVITY WITH RESPECT TO RAF-KINASE, CONTAINING CLAIMED COMPOUND AS ACTIVE INGREDIENT | 2011 |
|
RU2550038C2 |
| CALPAIN MODULATORS AND THEIR THERAPEUTIC USE | 2017 |
|
RU2773288C2 |
| ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | 2011 |
|
RU2535671C1 |
| COMPOSITIONS AND METHODS FOR JAK PATH INHIBITION | 2011 |
|
RU2672100C2 |
| 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5-HT3 MODULATORS | 2007 |
|
RU2448105C2 |
| PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
| PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2001 |
|
RU2340611C2 |
| DIAZACARBAZOLES AND METHODS OF APPLICATION | 2009 |
|
RU2515972C2 |
| BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | 2016 |
|
RU2738232C2 |
